Bausch Health Companies (NYSE:BHC - Get Free Report) is set to post its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect Bausch Health Companies to post earnings of $0.74 per share for the quarter. Bausch Health Companies has set its FY 2024 guidance at EPS.Persons that are interested in registering for the company's earnings conference call can do so using this link.
Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.14. The business had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. Bausch Health Companies's revenue was up 9.8% on a year-over-year basis. During the same period last year, the business posted $1.02 EPS. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Bausch Health Companies Trading Up 0.8 %
NYSE:BHC traded up $0.06 on Thursday, hitting $8.63. The company's stock had a trading volume of 2,793,166 shares, compared to its average volume of 2,792,184. Bausch Health Companies has a one year low of $5.57 and a one year high of $11.46. The firm has a market capitalization of $3.15 billion, a P/E ratio of -5.30 and a beta of 0.85. The stock has a fifty day moving average of $9.30 and a two-hundred day moving average of $8.16.
Analysts Set New Price Targets
BHC has been the topic of several research reports. Jefferies Financial Group decreased their target price on Bausch Health Companies from $16.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, February 20th. StockNews.com upgraded shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Wednesday, February 7th. Finally, Royal Bank of Canada cut their price objective on shares of Bausch Health Companies from $12.00 to $11.00 and set a "sector perform" rating for the company in a report on Tuesday.
View Our Latest Analysis on BHC
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Recommended Stories
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
